A sale of Boots to the Weston family at about $9 billion including debt would recover a large slice of the 2025 take-private within roughly a year of closing.
Sycamore Partners is close to selling Boots, the British pharmacy chain, to the Weston family in a deal that would value the business at about $9 billion including debt, according to people familiar with the matter. Talks are advanced and could conclude as soon as next week. Sycamore and Boots declined to comment.
The transaction would mark the first major realization from one of the largest retail take-privates in recent years. Sycamore acquired Walgreens Boots Alliance in 2025 in a deal valued at about $24 billion including debt, with roughly $10 billion of equity.
The math of the break-up
On enterprise value, Boots alone would fetch about 37.5% of what Sycamore paid for the whole company. Sycamore's own return will hinge on the equity value attached to Boots, a figure the parties have kept private. Even so, a sale of that size, about a year after closing, would give Sycamore a meaningful early return of capital while it retains the larger U.S. Walgreens business.
That is the logic of a carve-and-sell strategy. A buyer acquires a conglomerate at a price that reflects its weakest parts, then sells the units that command a premium from specialist or strategic owners. The approach has become more common as initial public offerings remain an unreliable exit for sponsor-owned companies.
Boots had other suitors and other paths. Australia's Sigma Healthcare held talks earlier this year before withdrawing, and a London listing had been considered. The Weston family offers something an IPO does not: a single buyer, a certain price and no exposure to equity-market volatility.
Why it matters beyond Boots
For limited partners, the deal is a test of whether mega take-privates can return capital on a reasonable timeline. Investors have pressed sponsors to show realizations rather than paper gains. A partial exit at scale would strengthen Sycamore's hand with its own investors and provide a template for other sponsors holding complex, multi-unit businesses.
The risk runs the other way for the remaining Walgreens business. Selling the international crown jewel first leaves the sponsor holding the U.S. pharmacy operation, which now has to carry the rest of the investment case on its own.
What to watch: A signed agreement and disclosure of the equity value. That figure, set against Sycamore's roughly $10 billion equity investment, is the number that will show whether the break-up is creating value or simply returning capital.